When it comes to cancer -- and really, life in general -- there are no guarantees.Yet Janssen-Cilag, a European drug manufacturer, is offering refunds to Britain's NHS if their drug Velcade doesn't prove effective, according to this. Velcade is shown to extend a cancer patients life by two years. The drug has been rejected because of its high cost but that decision might be reversed with the company's guarantee.

What do you think? Is this a marketing gimmick, or could this drug actually work?

The two drugs Velcade (bortezomib) and Revlimid (lenalidomide) are designed to treat the bone marrow cancer called multiple myeloma. A Phase I clinical trial has shown that the drugs may be more effective together than when used individually.

The trial was led by researchers at the Dana-Farber Cancer Institute in Boston. It included 38 patients who had their cancer recur despite other therapies. The patients were divided into groups that received successively higher doses of Velcade and Revlimid. Some patients also received the drug dexamethasone which can add to the anticancer effects of these two drugs.

Fifty-eight percent has responded to the combined treatment, six percent achieved complete remission. Researcher Dr. Paul Richardson said in a prepared statement "We are hopeful that this combination will prove to be a key therapeutic backbone in improving outcomes for our patients, both early and later in the course".

A type of Non-Hodgkin's lymphoma (NHL) called mantle cell lymphoma accounts for about five to ten percent of all lymphomas. According to an article recently published in the Journal of Clinical Oncology, Velcade (bortezobib) is an effective treatment option for patients with mantle cell lymphoma that has stopped responding to prior treatments.

Velcade is an agent known as a proteasome inhibitor. Proteasome inhibitors are drugs that block the action of proteasomes, proteins found in virtually all cells that regulate several aspects of cellular activity. By blocking the activity of proteasomes it can lead to the death of cancer cells. Bortezobib is the first therapeutic proteasome inhibitor to be approved for use in the United States.

Researchers conducted a clinical trial to evaluate Velcade in the treatment of fifteen patients with mantle cell lymphoma that has recurred or progressed following prior therapies. Anticancer responses occurred in 33 percent of patients and after over 13 months follow up, over half the patients were still surviving.